Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

NASDAQ:DSGN

Overview | Financials
Company Name Design Therapeutics, Inc.
Symbol DSGN
Currency USD
Price 4.67
Market Cap 264,417,735
Dividend Yield 0%
52-week-range 1.96 - 5.48
Industry Biotechnology
Sector Healthcare
CEO Mr. Pratik Shah Ph.D.
Website https://www.designtx.com

An error occurred while fetching data.

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to

Related Stocks

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.86 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

13.59 USD

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

uniQure N.V. logo

uniQure N.V.

QURE

5.42 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

7.71 USD

Replimune Group, Inc. logo

Replimune Group, Inc.

REPL

10.37 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.3 USD

Financials

Numbers are in millions USD

Numbers are in millions USD